CLINICAL_TRIALS
trial_result
· 2025-01-22
Clinical Trial Update: A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma [Phase 2]
Summary
Phase 2 study of tazemetostat in combination with HMPL-689 for relapsed/refractory lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hutchmed | Conditions: Relapsed/Refractory Lymphoma | Phase 2 | Status: COMPLETED